This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
Age ≥18 years.
Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).
Pancreatic tumor is surgically removed and
patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or
CA 19-9 non-producers, unless high-risk pathological features present.
Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC).
Radiographic evidence of metastatic disease.
Inability to ingest study drugs by mouth.
Medical College of Wisconsin
Lead sponsor